Graviton BioScience Corp, 2026-11-16
A new SEC Form D private-offering notice from New York, NY, a $75,000,000 filer-stated offering target in Biotech. The source filing is one click away.
What this filing says
Clinical-stage biotech developing selective ROCK2 inhibitors for fibrotic, autoimmune, and CNS diseases, including GV101 for Friedreich's ataxia.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Aoka LLC, 2026-11-16, $500K, Albany, NY
- JDI Pacific, 2026-11-16, $500K, Half Moon Bay, CA
- Alcar Inc., 2026-11-16, $6.5M, New York, NY
- Potentiam Biosciences, Inc., 2026-11-16, Irving, TX
- Transparency Analytics Inc., 2026-11-16, $5M, New York, NY
- Pelthos Therapeutics Inc., 2026-11-16, $57.5M, Durham, NC
- Stamp Free Ltd, 2026-11-16, $33K, Edinburgh
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.